HKPD

Cellyan Biotechnology Co., Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for cancer treatment. Headquartered in Hong Kong, the company specializes in chimeric antigen receptor T-cell (CAR-T) immunotherapy and other cellular immunotherapy platforms targeting hematologic malignancies and solid tumors. Cellyan's pipeline includes multiple CAR-T product candidates at various stages of clinical development, with lead programs addressing relapsed or refractory B-cell lymphomas and multiple myeloma. The company conducts research and development activities across facilities in Hong Kong and mainland China, collaborating with academic institutions and clinical centers to advance its therapeutic programs. Cellyan employs a business model centered on proprietary technology platforms that enable the design and manufacture of next-generation cell therapies with improved safety profiles and efficacy. The company holds several patents related to its CAR-T constructs and manufacturing processes. Recent developments include the progression of clinical trials for its lead candidates and expansion of its manufacturing capabilities to support commercial-scale production. Cellyan competes in the rapidly evolving cellular immunotherapy sector alongside both established pharmaceutical companies and emerging biotech firms, positioning itself through its focus on the Greater China market and partnerships with regional healthcare providers.